NEW YORK, April 11, 2024 /PRNewswire/ --Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States.

纽约，2024年4月11日/PRNewswire/--先进声学心脏诊断领域的领导者Acarix宣布启动第一项基于美国的临床研究，以收集真实世界的数据，以比较传统压力测试和CADScor系统之间的工作流程。重点是确定胸痛患者的非阻塞性冠状动脉疾病（CAD），最终目标是改善美国急诊科和诊所的出院情况。

.

.

The clinical study will collect data from 200 patients at the University of California, Davis, being assessed for chest pain in both the emergency department and outpatient cardiology clinic. The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilizing the CADScor System to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests.

这项临床研究将收集加州大学戴维斯分校200名患者的数据，这些患者在急诊科和门诊心脏病诊所接受胸痛评估。与传统的压力成像测试相比，该研究将通过利用CADScor系统识别胸痛患者的非阻塞性冠状动脉疾病来评估成本效益，节省时间和减少副作用的潜在改善。

Patient enrollment for the study will commence in early Q2 2024, marking a crucial step forward in advancing our understanding of the CADScor System in various clinical workflows in the United States..

该研究的患者登记将于2024年第二季度初开始，这标志着我们在美国各种临床工作流程中加深对CADScor系统的理解迈出了关键的一步。。

'For this study, we are evaluating the CADScor System to see if it offers patients an alternative to the standard stress test,' stated Dr. Surabhi Madwhal Atreja, M.D., F.A.C.C., R.P.V.I., Health Sciences Clinical Professor, University of California, Davis and Principal Investigator. 'Based on the findings, this study may be foundational for rapid assessment of non-obstructive CAD, streamlining ER processes, and establishing an algorithm at UC Davis Medical Center for the safe discharge of low-risk chest pain patients, saving time and avoiding unnecessary tests and radiation hazards for our patients.'.

“在这项研究中，我们正在评估CADScor系统，看看它是否为患者提供了标准压力测试的替代方案，”医学博士Surabhi Madwhal Atreja博士，F.A.C.C.，R.P.V.I.，加利福尼亚大学戴维斯分校健康科学临床教授兼首席研究员说道根据这些发现，这项研究可能是快速评估非梗阻性CAD，简化ER过程以及在加州大学戴维斯分校医学中心建立算法的基础，以安全排出低风险胸痛患者，节省时间并避免不必要的测试和辐射危害我们的患者。”。

'I am pleased to see the initiation of the first US study for the CADScor System, focused on potential efficiency improvements in the clinical and healthcare economic outcomes. This crucial step marks a significant milestone in establishing the system's real-world relevance in the United States healthcare system,' stated Acarix President & CEO Aamir Mahmood.

“我很高兴看到美国针对CADScor系统的第一项研究开始，该研究侧重于临床和医疗保健经济结果的潜在效率改进。Acarix总裁兼首席执行官艾米尔·马哈茂德（AamirMahmood）表示，这一关键步骤标志着该系统在美国医疗保健系统中建立现实意义的重要里程碑。

'The study not only underscores our commitment to advancing cardiovascular care, but we also believe this study will increase awareness of the CADScor System benefits in the United States.'.

“这项研究不仅强调了我们对推进心血管护理的承诺，而且我们还相信这项研究将提高人们对美国CADScor系统益处的认识。”。

For more information, contact:

有关更多信息，请联系：

Jennifer Anderson, Head of Marketing & Communications

Jennifer Anderson，营销与传播主管

phone +1 720 471 4625 email Jennifer.anderson@acarix.com

电话+1 720 471 4625电子邮件Jennifer.anderson@acarix.com

About Acarix

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures.

Acarix是一家瑞典医疗器械公司，致力于在护理点快速排除冠状动脉疾病（CAD）的解决方案的创新。CE批准且FDA DeNovo批准的Acarix CADScor系统适用于疑似CAD胸痛的患者，旨在帮助减少数百万不必要的，侵入性的和昂贵的诊断程序。

The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care.

CADScor系统已用于29000多名患者。Acarix推荐CADScor系统作为一线诊断辅助设备，该系统使用高度敏感的声学和先进的计算处理来分析冠状动脉血流，以排除严重的冠状动脉疾病（CAD），在护理点至少有96%的确定性。

Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com.

Acarix在斯德哥尔摩的Nasdaq First North Premier成长市场上市（股票代码：Acarix）。卡内基投资银行是Acarix的认证顾问。有关更多信息，请访问www.Acarix.com。

View original content to download multimedia:https://www.prnewswire.com/news-releases/acarix-announces-the-initiation-of-the-first-us-based-clinical-workflow-evaluation-study-302113726.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/acarix-announces-the-initiation-of-the-first-us-based-clinical-workflow-evaluation-study-302113726.html

SOURCE Acarix

源Acarix

Company Codes: Stockholm:ACARIX

公司代码：斯德哥尔摩：ACARIX